SJP-005, a new product that is being developed as a pain treatment and for opioid use disorder, is a combination product of an antihistamine drug with Toll-like receptor 4 (TLR4) inhibition properties (ketotifen), and a non-steroidal anti-inflammatory drug (NSAID) which also possesses peroxisome proliferator-activated gamma receptor (PPAR-γ) agonist activity (ibuprofen) [10,11]. Here, TLR4 is linked to opioid use disorder.